As of Wednesday close, Revance Therapeutics Inc.’s (NASDAQ:RVNC) stock was down -$0.4, moving down -2.19 percent to $17.87. The average number of shares traded per day over the past five days has been 925,900 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.74 fall in that time frame. In the last twenty days, the average volume was 1,550,100, while in the previous 50 days, it was 1,376,828.
Since last month, RVNC stock retreated -22.44%. Shares of the company fell to $16.93 on 08/22/23, the lowest level in the past month. A 52-week high of $37.98 was reached on 05/09/23 after having rallying from a 52-week low of $16.93. Since the beginning of this year, RVNC’s stock price has dropped by -3.20% or -$0.59, and marked a new high 13 times. However, the stock has declined by -52.95% since its 52-week high.
RVNC stock investors should be aware that Revance Therapeutics Inc. (RVNC) stock had its last reported insider trading activity 28 days ago on Aug 03. Foley Mark J, the CEO of the company, disposed of 26,279 shares for $22.57 on Aug 03. It resulted in a $593,151 divestment by the insider. Foley Mark J sold 26,279 shares at an average price of $24.94 on Jul 03. The insider now owns 866,654 shares following the transaction. On Jul 03, CFO Schilke Tobin sold 1,701 shares at $25.04 apiece. The transaction was valued at $42,593.
Valuation Metrics
The stock’s beta is 0.80. Besides these, the trailing price-to-sales (P/S) ratio of 8.46, the price-to-book (PB) ratio of 55.84.
Financial Health
In the three months ended June 29, Revance Therapeutics Inc.’s quick ratio stood at 4.70, while its current ratio was 5.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 14.19, and the total debt-to-equity ratio was 14.77. On the profitability front, the trailing twelve-month gross margin is 61.50% percent. Based on annual data, RVNC earned $80.9 million in gross profit and brought in $132.56 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -87.30%. Return on equity (ROE) for the past 12 months was -903.30%.
In Revance Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $380.35 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. RVNC’s revenue rose 51.2% to $49.33 million during the quarter, while net income inched up to $58.13 million. While analysts expected Revance Therapeutics Inc. to report -$0.78 quarterly earnings, the actual figure was -$0.8 per share, beating the consensus estimate by -2.60%. During the quarter, the company generated -$62.9 million in EBITDA. The liabilities of Revance Therapeutics Inc. were 570.75 million at the end of its most recent quarter ended June 29, and its total debt was $432.39 million. The value of shareholders’ equity is $87.95 million.
Technical Picture
This quick technical analysis looks at Revance Therapeutics Inc.’s (RVNC) price momentum. With a historical volatility rate of 29.18%, the RSI 9-day stood at 32.11% on 30 August.
With respect to its five-day moving average, the current Revance Therapeutics Inc. price is down by -3.98% percent or -$0.74. At present, RVNC shares trade -19.10% below its 20-day simple moving average and -47.49% percent below its 100-day simple moving average. However, the stock is currently trading approximately -37.95% below its SMA50 and -22.20% below its SMA200.
Stochastic coefficient K was 29.60% and Stochastic coefficient D was 28.74%, while ATR was 0.93. Given the Stochastic reading of 27.25% for the 14-day period, the RSI (14) reading has been calculated as 32.34%. As of today, the MACD Oscillator reading stands at 0.05, while the 14-day reading stands at -0.17.
Analyst Ratings
Exane BNP Paribas upgraded its rating on Revance Therapeutics Inc. (NASDAQ: RVNC) to a Neutral in a note to investors on August 16, 2023. The analysts firm previously had an Underperform rating on the stock.Revance Therapeutics Inc. (RVNC) has been rated Buy by analysts. According to 0 brokerage firms, RVNC is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Revance Therapeutics Inc. stock as buy, with 9 recommending it as overweight.
With a median target price of $40.00, the current consensus forecast for the stock is $20.00 – $65.00. Based on these forecasts, analysts predict Revance Therapeutics Inc. (RVNC) will achieve an average price target of $39.83.
